Diversified Consumer Services
Company Overview of Stanford University
Stanford University is an educational and research institution that provides academic programs in sciences and interdisciplinary areas. The university offers graduate, undergraduate, executive, professional, continuing, and K-12 education. It focuses on areas such as earth sciences, engineering, humanities and sciences, business, education, law, and medicine. The university also provides research facilities that include Center for Advanced Study in the Behavioral Sciences, National Bureau of Economic Research, Stanford Linear Accelerator Center, Woods Institute for the Environment, Freeman Spogli Institute for International Studies, and Stanford Institute for Creativity and the Arts. Stanfor...
450 Serra Mall
Stanford, CA 94305-2004
Founded in 1885
Key Executives for Stanford University
President and Member of Board of Trustees
Chairman and a Professor of the Department of Ophthalmology
Vice Provost for Academic Affairs and Deputy Chairman of Selection Committee
Dean of Freshmen and Transfer Students
Compensation as of Fiscal Year 2015.
Stanford University Key Developments
Eiger BioPharmaceuticals Acquires License from Stanford University to Pulmonary Arterial Hypertension Program
Nov 11 15
Eiger BioPharmaceuticals has acquired an exclusive license to pulmonary arterial hypertension program from Stanford University in the US. The technology targets effects of leukotriene B4 for modulating inflammation and immune response in the lung, providing a potential therapeutic approach to treat PAH. Eiger committed to undertake a clinical study to assess if blocking the effects of LTB4 may be a useful new treatment for PAH.
Stanford University Presents at 14th Annual BIO Investor Forum, Oct-20-2015
Oct 16 15
Stanford University Presents at 14th Annual BIO Investor Forum, Oct-20-2015 . Venue: Parc 55 Hotel, San Francisco, California, United States.
Abeona Therapeutics Inc. and Stanford University Sign License Agreement for Fanconi Anemia Drug
Oct 14 15
Abeona Therapeutics Inc. has signed a license agreement with Stanford University for an adeno-associated virus, or AAV, delivery vector for the treatment of Fanconi anemia, or FA. This license augments a previously announced license agreement with the University of Minnesota for ABO-301 (AAV-FANCC) to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases. ABO-301 is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective gene to cells of the hematopoietic or blood system with the aim of reversing the effects of the genetic errors that cause Fanconi anemia.
Similar Private Companies By Industry
Recent Private Companies Transactions